Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model

The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could retain partial activity against recent omicron sub-lineage such as BA.5 variants, including BQ.1.1. Here we report full efficacy of Sotrovimab against BQ.1.1 viral replication as measure by RT-qPCR in a non-human primate challengemodel.

Automated summary

The SARS-CoV2 Omicron variants have acquired new Spike mutations that make them resistant to most currently available monoclonal antibody treatments, limiting options for severe Covid-19 patients. However, recent data suggests that Sotrovimab may still be partially effective against the BA.5 variants, including BQ.1.1. In a non-human primate challenge model, Sotrovimab showed full efficacy in inhibiting BQ.1.1 viral replication as measured by RT-qPCR.